1. 1. Perk J, DeBacker G, Gohlke H, Graham I, Reiner Z, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635-1701. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22698795
2. 2. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9987089
3. 3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel-lII). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII) final report. Circulation. 2002; 106: 3143-3421. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12485966
4. 4. Stone NJU, Robinson J, Lichtenstein AH, BaireyMerz CN, Blum CB, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2889-2934. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24239923
5. 5. International Atherosclerosis Society (IAS) Harmonized guidelines on prevention os atherosclerotic cardiovascular diseases. 2003; http://www.athero.org/